The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.

(2022) Heinz-Josef Lenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer

(2022) Irem Ozel et al.   Cancers

Exploring the Intracrine Functions of VEGF-A

(2021) Sophie Wiszniak et al.   Biomolecules

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

(2021) Robert Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis

(2021) Yasser Tabana et al.   Frontiers in Oncology

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

(2021) Chuanliang Cui et al.   npj Genomic Medicine

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial

(2021) Michiel S. van der Heijden et al.   EUROPEAN UROLOGY

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

(2021) S. Sugawara et al.   ANNALS OF ONCOLOGY

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

(2021) Alexander Bagaev et al.   CANCER CELL

Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.

(2021) Jermaine Coward et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer

(2021) Dongqiang Zeng et al.   Journal for ImmunoTherapy of Cancer

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

(2021) Christian Marth et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

(2021) Ann-Lii Cheng et al.   JOURNAL OF HEPATOLOGY

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

(2021) Robert J. Motzer et al.   JAMA Oncology

374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

(2021) Kevin Tyan et al.   Journal for ImmunoTherapy of Cancer

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

(2020) Hanne Lind et al.   Journal for ImmunoTherapy of Cancer

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

(2020) T.K. Choueiri et al.   ANNALS OF ONCOLOGY

Acquired Resistance to Immune Checkpoint Inhibitors

(2020) Adam J. Schoenfeld et al.   CANCER CELL

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

(2020) D. Ciardiello et al.   ANNALS OF ONCOLOGY

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

TGFβ biology in cancer progression and immunotherapy

(2020) Rik Derynck et al.   Nature Reviews Clinical Oncology

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

(2020) Catherine S. Grasso et al.   CANCER CELL

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

TGF-β suppresses type 2 immunity to cancer

(2020) Ming Liu et al.   NATURE

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

(2020) Shun Li et al.   NATURE

The hallmarks of cancer are also the hallmarks of wound healing

(2020) Lucy MacCarthy-Morrogh et al.   Science Signaling

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

(2020) Anusha Kalbasi et al.   Science Translational Medicine

Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures

(2019) Dongqiang Zeng et al.   Cancer Immunology Research

Specificity, versatility, and control of TGF-β family signaling

(2019) Rik Derynck et al.   Science Signaling

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

The Intersection between Tumor Angiogenesis and Immune Suppression

(2019) Osama E. Rahma et al.   CLINICAL CANCER RESEARCH

Transforming Growth Factor-β Signaling in Immunity and Cancer

(2019) Eduard Batlle et al.   IMMUNITY

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

(2019) Brian I Rini et al.   LANCET

Application of PD-1 Blockade in Cancer Immunotherapy

(2019) Xiaomo Wu et al.   Computational and Structural Biotechnology Journal

Rebalancing Immune Homeostasis to Treat Autoimmune Diseases

(2019) David A. Horwitz et al.   TRENDS IN IMMUNOLOGY

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

(2019) Chang Gon Kim et al.   Science Immunology

Optimizing immunotherapy for gynecologic cancers

(2019) Maria M. Rubinstein et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

(2018) Julius Strauss et al.   CLINICAL CANCER RESEARCH

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis

(2018) Italia Grenga et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

(2018) Catherine S. Grasso et al.   Cancer Discovery

Anti-Angiogenics: Current Situation and Future Perspectives

(2018) Katja Zirlik et al.   Oncology Research and Treatment

Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.

(2018) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer

(2018) Y-J Bang et al.   ANNALS OF ONCOLOGY

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

(2018) Ankur Chakravarthy et al.   Nature Communications

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection

(2017) Shomyseh Sanjabi et al.   Cold Spring Harbor Perspectives in Biology

TGF-β Family Signaling in Tumor Suppression and Cancer Progression

(2017) Joan Seoane et al.   Cold Spring Harbor Perspectives in Biology

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Transforming growth factor-β: A therapeutic target for cancer

(2017) Sulsal Haque et al.   Human Vaccines & Immunotherapeutics

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Learning from PD-1 Resistance: New Combination Strategies

(2016) Xia Bu et al.   TRENDS IN MOLECULAR MEDICINE

Structural Biology and Evolution of the TGF-β Family

(2016) Andrew P. Hinck et al.   Cold Spring Harbor Perspectives in Biology

The Discovery and Early Days of TGF-β: A Historical Perspective

(2016) Harold L. Moses et al.   Cold Spring Harbor Perspectives in Biology

Regulation of TGF-β Family Signaling by Inhibitory Smads

(2016) Keiji Miyazawa et al.   Cold Spring Harbor Perspectives in Biology

Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins

(2016) Ian B. Robertson et al.   Cold Spring Harbor Perspectives in Biology

TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology

(2016) Masato Morikawa et al.   Cold Spring Harbor Perspectives in Biology

VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread

(2016) Xiujuan Li et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis

(2016) W. Liang et al.   Cancer Immunology Research

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

(2015) Alexandre Calon et al.   NATURE GENETICS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

(2015) Marianna Papaspyridonos et al.   Nature Communications

TGFβSignaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis

(2015) Panagiotis Papageorgis   Journal of Oncology

T cell- but not tumor cell-produced TGF-β1 promotes the development of spontaneous mammary cancer

(2015) Abira Sarkar et al.   Oncotarget

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

A Long Noncoding RNA Activated by TGF-β Promotes the Invasion-Metastasis Cascade in Hepatocellular Carcinoma

(2014) Ji-hang Yuan et al.   CANCER CELL

TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis

(2014) D. R. Principe et al.   JNCI-Journal of the National Cancer Institute

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells

(2014) Sarah K Maenhout et al.   OncoImmunology

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β Signalling Is Required for CD4+ T Cell Homeostasis But Dispensable for Regulatory T Cell Function

(2013) Anna Śledzińska et al.   PLOS BIOLOGY

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

(2013) Aleksandra M. Dudek et al.   Frontiers in Immunology

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

Molecular Pathways: Targeting the TGF-  Pathway for Cancer Therapy

(2012) A. L. Smith et al.   CLINICAL CANCER RESEARCH

VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd

(2012) Zuyue Sun et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TGF-β – an excellent servant but a bad master

(2012) Lenka Kubiczkova et al.   Journal of Translational Medicine

Absence of signaling into CD4+ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3+ regulatory T cells

(2012) Michael G Strainic et al.   NATURE IMMUNOLOGY

Tgf-β1 produced by activated CD4+T Cells Antagonizes T Cell Surveillance of Tumor Development

(2012) Moses K. Donkor et al.   OncoImmunology

Non-Smad signaling pathways

(2011) Yabing Mu et al.   CELL AND TISSUE RESEARCH

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

(2011) Andrea Facciabene et al.   NATURE

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth

(2011) T J Standiford et al.   ONCOGENE

The dynamic roles of TGF-β in cancer

(2010) Erik Meulmeester et al.   JOURNAL OF PATHOLOGY

Why are tumour blood vessels abnormal and why is it important to know?

(2009) J A Nagy et al.   BRITISH JOURNAL OF CANCER

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

The TGF-β paradox in human cancer: an update

(2009) Maozhen Tian et al.   Future Oncology

TGFβ in Cancer

(2008) Joan Massagué   CELL

Roles of TGFβ in metastasis

(2008) David Padua et al.   CELL RESEARCH

TGF-β signaling in vascular biology and dysfunction

(2008) Marie-José Goumans et al.   CELL RESEARCH

Transforming growth factor-  signaling and ubiquitinators in cancer

(2008) E. Glasgow et al.   ENDOCRINE-RELATED CANCER

The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner

(2008) Alessandro Sorrentino et al.   NATURE CELL BIOLOGY

Cancer as an overhealing wound: an old hypothesis revisited

(2008) Matthias Schäfer et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY